Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02452814 · ClinicalTrials.gov registry record
Long Term Extension Study is Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection
A clinical trial of HCV, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- 8
- Enrollment target
- 3
- Study locations
NCT02452814: Completed study of HCV, sponsored by Hoffmann-La Roche.
NCT02452814 is a study of HCV that has completed, run by Hoffmann-La Roche. The registered enrollment target is 8 participants, below the 198-participant average among 8 other HCV trials with a reported enrollment target (96% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02452814, a study of HCV, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- 8 participants
- Enrollment target
- 3
- Study locations
Study Summary
Long Term Observational Extension Study Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium in Combination with Telaprevir and Ribavirin in Subjects with Chronic Hepatitis C Virus Genotype 1 Infection
Conditions Studied
Study Locations (3)
Texas
- Methodist Transplant Physicians - Dallas
- Research Specialists of Texas - Houston
Other
- Fundacion de Investigacion de Diego - San Juan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2014-05-07 |
| Est. Completion | 2017-05-03 |
What the finished NCT02452814 record still lists
NCT02452814 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 198-participant average among 8 other HCV trials with a reported enrollment target (96% lower).
The record links to 1 condition, with HCV appearing as the primary indexed condition, and to 0 interventions.
NCT02452814 reports a single indexed study location in Texas, Other.
Frequently Asked Questions
What is clinical trial NCT02452814 about?
NCT02452814 is a clinical study titled "Long Term Extension Study is Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection". Long Term Observational Extension Study Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium in Combination with Telaprevir and Ribavirin in Subjects with Chronic Hepatitis C Virus Genotype 1 Infection
What is the current status of trial NCT02452814?
This trial is currently completed. The enrollment target is 8 participants. The study started on 2014-05-07. Estimated completion is 2017-05-03.
What conditions does trial NCT02452814 study?
This clinical trial studies the following conditions: HCV.
Who is sponsoring clinical trial NCT02452814?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02452814 being conducted?
This trial has 3 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HCV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02452814's enrollment target sits among peer trials
8 9th of 8 the lowest of 8 other HCV trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HCV trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Prophylaxis With Direct-acting Antivirals for Kidney Transplantation From HCV-Infected Donors to Uninfected Recipients
RECRUITING · NA
-
A Setting Focus Overdose Prevention Intervention
RECRUITING · NA
-
Appalachian Partnership to Reduce Disparities (Aim 2)
RECRUITING · NA
-
Hepatitis C Treatment to Prevent HIV, Initiate Opioid Substitution Therapy, and Reduce Risky Behavior
ACTIVE NOT RECRUITING
-
The Ganchero Intervention for Migrant People Who Inject Drugs From Puerto Rico in New York City
ACTIVE NOT RECRUITING · NA
-
Integrated HIV Prevention and HCV Care for PWID
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI